Trial Profile
A Randomized, Controlled Trial Comparing the Effect of Exenatide, Sitagliptin or Glimepiride on Functional beta-Cell Mass in Patients With Impaired Fasting Glucose or Early Type 2 Diabetes.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Exenatide (Primary) ; Sitagliptin (Primary) ; Glimepiride
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 01 Nov 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 08 Nov 2008 New trial record.